Howard Fillit: I agree that access to models in AD is a problem, too. The models remain expensive, and some are limited by intellectual property and licensing issues. I wonder if that is as true in other disease states.
Eli Michaelis: Jens, I agree with Howard that the difficulty is not in identifying new targets but in moving to studies with good animal models and conducting the appropriate pharmacokinetic as well as pharmacodynamic studies. If the work is not done correctly, it would be difficult to raise money to move further along the chain of funding.
Cynthia Joyce:
We would like to learn about new ideas for managing intellectual property (IP) transfer from academia to industry. Our foundation is trying to recruit industry to the drug development effort for spinal muscular atrophy (SMA), and the technology transfer process is consuming an inordinate amount of time.
Jens Eckstein: From a venture capital point of view, the less bureaucratic tech transfer is, the better. Technology licensing offices (TLOs) have a pretty bad reputation in the industry and are perceived more as a nuisance. One reason for this is that a lot of them have the mandate from the universities to raise funds rather than get technology out the door.
Cynthia Joyce: That has been our experience. This is a significant bottleneck to doing the pharmacokinetic and pharmacodynamic studies you are discussing. Is there any movement on reducing the bottleneck on licensing models for drug testing?
Jens Eckstein: When talking about targets, one of the key questions remains validation -clinical validation, that is.
Eli Michaelis: Jens, clinical validation could benefit from a universal acceptance of surrogate markers for the disease. This is still lacking in this field.
Gabrielle Strobel: One often reads that the industry over the past 5 years or so has raised its bar on what kind of validation it expects before it considers taking on an academic project. Where is that bar now? What do you have to show?
Jens Eckstein: Validation in our shop means that one sees a clinical effect when hitting the target, that is, Phase 2 data or in some instances, Phase 1b data.
Howard Fillit: As Eli points out, while cognition is a "valid" clinical outcome, we do not have valid biological outcomes. That is a big problem for AD in moving from animals to humans. One unique problem in AD that we always talk about is that "mice do not write books." There was recently a conference on trying to identify cognitive tests that translate well from mice to humans.
Jordan Tang: Animal model work is definitely a slow step, although in working at drug targeting at the initial step of AD pathogenesis, the problem may not be as severe. There are very limited models available for academic laboratories for cognitive tests.
Greg Brewer: It seems that many problems with human trials are neurological issues. Does anyone have an idea how many and how to monitor these better in animal models, for example, pain, blurred vision, confusion?
Eli Michaelis: I agree with Howard that there are improvements being made in behavioral methodology. I would like to comment again on being able to perform good pharmacokinetic and pharmacodynamic studies on normal animals, and animal models of the disease are a prerequisite; otherwise, the results may be too "risky" for a company to invest substantial amounts of money.
Gabrielle Strobel: Eli, how do you recommend an academic investigator -say, a molecular biologist in neuroscience -should approach toxicological and pharmacological testing of a compound he or she considers promising? How does one start this important piece of the package?
Eli Michaelis: Gabrielle, there are a few academic centers that are fully equipped to conduct pharmacokinetic studies and early toxicological studies. There are also several companies that perform these types of studies. What is needed is some early-stage financing that will allow for the conduct of such studies.
Gabrielle Strobel: Eli, is this a niche for foundations?
Eli Michaelis: Gabrielle, yes.
Jens Eckstein: In my opinion, it would be better to focus on safety parameters in the preclinical studies and then push into humans as quickly as possible. New biomarkers might make this move more feasible in the future, since one could get surrogate readouts earlier in clinical development.
Gabrielle Strobel: Amyloid imaging biomarkers are being tested in humans, but they are based on positron emission tomography (PET) and are expensive.
Howard Fillit: I personally "believe" PET amyloid imaging could change the paradigm, at least for targets on amyloid. In addition, similar imaging modalities for tangles or neuronal markers are on the horizon. Here is a factoid to consider that I think is still reasonably true. Of about 250 drugs approved by the Food and Drug Administration (FDA) in the past 5 years, only around 10 were for central nervous system (CNS) diseases, all symptomatic therapies, and none were disease-modifying, so it is not just AD, but neurological disease in general.
Jan Teller:
Howard, what, in your opinion, is the reason for so few CNS drugs approved by the FDA?
Howard Fillit: It is not the approval process; it is the ability of science/pharma/biotechs to deliver agents for approval to the FDA. These are difficult diseases and targets. I think outcome measures are secondary issues.
Jordan Tang: For an academic molecular biologist, it would probably take a very serious drug candidate before toxicology and pharmacokinetics can be considered. Besides, these tests are usually more expensive than the grant can support. So, some kind of commercial outfit needs to be organized. These all make it a difficult task.
Frank Longo: A potential important asset might be an National Institutes of Health (NIH)-funded mechanism/service in which a large number of investigators with multiple potential targets could assess compounds in animal models using a critical mass of expertise in trial design, pharmacokinetics, and toxicology. This would also allow some comparative function.
Howard Fillit: Of course, the Institute for the Study of Aging (ISOA) has given about $24 million to over 130 "high-risk" early-stage drug discovery programs during the past 5 years. We have also supported some pharmacokinetics/pharmacodynamics toxicology,GMP (Good Manufacturing Practice) synthesis, etc. There is a great demand for our funding, and we are trying to raise money to meet this need through a new public charity. The demand from academia and biotech, in my opinion, demonstrates that it is not a lack of ideas; it is a lack of funding.
Jens Eckstein: I agree that independent new drug (IND)-enabling toxicology is usually too expensive for research grants. This is a place the NIH should really focus on since they have the resources as well as the expertise for these studies.
June Kinoshita: Frank seems to have suggested that the NIH can also play a role by funding core centers to provide these services to academics. Do you know of actual moves afoot within NIH to do this?
Howard Fillit: I think the National Institute on Aging (NIA) does have a program for supporting toxicology studies now.
Jordan Tang: The NIH Translational Research Award seems to be designed to do some of the preclinical studies.
Eli Michaelis: Jordan, if a scientist has access to other scientists with expertise in pharmacokinetics and toxicology studies, these early studies can be carried out in academic settings for considerably less money than in industrial settings.
Frank Longo: Another key challenge for many is behavioral and cognitive assessment in animal models. There seem to be some commercial sources, but it is expensive and it is hard to execute animal work off-site.
Jens Eckstein: When working with academic laboratories on IND-enabling studies, it is very important to include someone who has done INDs and clinical development. There are a lot of tricks and pitfalls. Pharma people are a great resource in this respect.
Howard Fillit: Jens, I agree that most academic and some early-stage biotech companies lack expertise in preclinical and clinical development. Partnering is definitely key, and planning needs to start early on.
Frank Longo: Even when one can access the technical capabilities, I have been amazed at how many opinions one can get on the best preclinical, IND-type strategies. It would be nice to have a consulting team to go to for advice.
Howard Fillit:
In response to Frank's comments, the "drug discovery services" industry is now out there. What are people's experiences in consulting with them?
Eli Michaelis: Frank, I agree with you that this is a complex process and nothing is immediately obvious, including the opinions you receive. In our experience, we have found that if we have conducted some good studies of pharmacokinetics and have evidence of good pharmacodynamic properties without obvious short-term toxicology, then pharma companies become interested in co-funding or helping to launch a company for the further testing and development of a drug.
Jens Eckstein: I would also like to point out that VCs (venture capitalist firms) can be a great resource, since they usually view the IND-enabling studies as one of the key components for an investment. They are very well connected and are in the people business.
Jan Teller: Could someone comment on the applicability/validity of non-vertebrate testing in CNS diseases and its current perception by pharma and the FDA?
Frank Longo: The jump from mouse to human has been so difficult; I imagine an even larger jump is more difficult, but on the other hand, the elegance of some of the invertebrate models is impressive.
Eli Michaelis: Jan, non-vertebrate testing is, I believe, still a long way away from being accepted as a substitute to vertebrate testing.
Howard Fillit: Non-vertebrate testing has value for target validation in a biological sphere. But worms do not write books. That is the problem.
Frank Longo: I think Eli is right. One interesting area, though, is the potential ability to screen large numbers of compounds with invertebrate models; thus, what one loses in increased risk of applicability might be gained with the increment in numbers.
Greg Brewer: What are your opinions about getting a pre-IND plan from an FDA consultant versus your own or a consulting firm?
Jens Eckstein: The most important issue when working with contract research organizations (CROs) is project management; one should not rely on their internal expertise, since ultimately they need to earn money and have a kind of "conflict of interest" to do only what is necessary.
Frank Longo: I have had some good experiences in getting specific services; others are too expensive. Getting advice on the big picture requires some networking; I have no experience with the FDA.
Jens Eckstein: Pre-IND meetings are wonderful, although they do now (or early next year?) cost money. It is absolutely essential to establish a personal rapport with the FDA folks working on your IND and clinical trial, and a lot of mistakes and misunderstandings can be cleared away.
Jordan Tang: Our experience is to do all the toxicology and pharmacokinetics within the framework of a new startup. It enabled us to connect with expert service and advice. We would not be able to do it without a new venture.
Jens Eckstein:
The problem is that it is very difficult to raise VC money with a new target idea and no clinical data.
June Kinoshita: To all, is drug delivery across the blood-brain barrier (BBB) a major obstacle to CNS drug development? One would think so, but many academic scientists I have spoken with seem to blithely assume that once they have come up with a compound, it is not a big deal for pharma to get it across the BBB. Does the neurodegeneration field (and its funding sources) need a wake-up call on this issue?
Howard Fillit: The BBB is a problem; there is no doubt. But I think we are learning more and more about the chemical properties of compounds that can cross, and how to design them.
The earlier people with novel compounds hook up with formulation/delivery people, the better.
Jordan Tang: For people in pharma who are working on drugs, BBB penetration is a big problem. It requires the design of very small molecules which are not compatible with many of the other good properties for a drug.
Eli Michaelis: June, you are right about the BBB being a true "barrier" to CNS drug development. But, it is not true that neuroscientists in the area of drug development have ignored that. I know that our scientists have developed in vitro models of the BBB that are used routinely, early in the drug design process, in order to select the best candidates for further development.
Frank Longo: The BBB problem is critical for VC. The medicinal chemistry costs and the uncertainty of whether a compound can be modified appropriately change the cost/risk equation.
Eli Michaelis: I would recommend to all to pay very close attention to the brain delivery issue. Big pharma has learned that lesson very well. Most failures in drug development have been associated with problems in delivery.
Jordan Tang: BBB is just one of the many problems. Selectivity is also a critical problem and, previously mentioned, toxicology and pharmacokinetics. Then there is oral availability. The problem is how to incorporate all these good properties in a small molecule.
Frank Longo:
We recently had a series of compounds assessed commercially for BBB penetration in vivo in mice. The cost was about $10,000 for each compound.
Howard Fillit:
We have certainly seen programs in which animal model studies are proposed, without data on whether the compounds get into the brain. That is bad.
Frank Longo: It is expensive to obtain measurements of compounds in the CNS; thus, I imagine there are many unpublished studies of compounds not working in which the CNS bioavailability was not certain.
Eli Michaelis: June, the reason why I mentioned that pharmacokinetics studies should be done early on is so that direct measures of penetration can be made. Preferably, if scientists have access to BBB cell models, they will have determined if drugs do or do not penetrate the BBB so they do not reach the wrong conclusions.
June Kinoshita: Eli, are such BBB cell models readily available to academic scientists?
Eli Michaelis: June, the models have been around for nearly two decades and can be established in academic laboratories. Our scientists have been conducting workshops for academic and industrial scientists to teach them how to set up these models.
Jens Eckstein: I think that the BBB problem is one piece of the puzzle. As for our shop, we are more concerned about mechanism of action/efficacy than the BBB. In our experience, the formulation/delivery folks can do wonders.
Eli Michaelis: Jens, the issue is not that you would equate rodent to human pharmacokinetics. It is that you would know how to interpret your pharmacodynamic results if you know how the pharmacokinetics profile is in the experimental animal you are using.
Jens Eckstein: Fair enough, Eli. But again, I would circumvent the pharmacodynamic/pharmacokinetics issue as long as possible and show efficacy by direct delivery.
Jordan Tang:
We have used the cell model of BBB but still wanted to know how it comes out in an animal model. With the power of mass spectrometry, it is not too difficult to measure drugs in the brain.
Howard Fillit: I agree with Eli; the models have been around a long time, but I do not know about actual data on how predictive they are of clinical success.
Eli Michaelis: Howard, in our experience they are quite accurate, including the prediction of the pathway for the block in BBB transfer.
Howard Fillit: Another approach is using PET in early-stage clinical studies with labeled drug. I have seen that done.
Jens Eckstein: PET is unfortunately very expensive and clinicians have been very slow in adopting PET in clinical trials.
Howard Fillit: For AD, if the target is amyloid, I would prefer to see a change in amyloid deposition, for example. Rodent cognition testing is very poorly predictive of human success, as I understand the data.
Gabrielle Strobel: Howard, that is interesting. Can you elaborate? Do you mean Pittsburgh compound B (PIB) being used in AD trials?
Howard Fillit: PIB is good for amyloid imaging, but if one is trying to expedite pharmacokinetics/pharmacodynamics in humans, in CNS, PET may be useful with some drugs that, for example, affect metabolism neurochemistry. That is, distinguish PIB as a biomarker study from the issues around; does a drug get into human brain and where in brain does it go?
Frank Longo: I think that significant sensitivity and specificity issues remain with PET, even with the labeled compounds that bind amyloid.
Jens Eckstein: I should add that PET is especially expensive in the US. In Australia or New Zealand, PET costs a third or even a fourth of the US price tag.
Gabrielle Strobel: One Australian center reported initial results of exploring the use of PIB in AD and related dementias at a conference earlier this year.
Greg Brewer: Given the BBB problem, is there any receptivity to craniotomy and direct injection or longterm pumping for chronic problems?
Howard Fillit: I do not think craniotomy is a promising way to go, or direct injection. But I think intranasal delivery looks very promising, especially new work in the last couple of years on this delivery method.
Eli Michaelis: Greg, if that is the only way to get it in there and it is a serious disease, maybe. However, I agree with Howard about the intranasal route.
Howard Fillit: There is hope for nanotechnology in delivery across the BBB.
Jens Eckstein: Intranasal delivery really has huge potential.
June Kinoshita: Do you think some promising compounds are being written off too soon because animal studies do not properly take into consideration the formulation and delivery issue? That is, do you worry that inattention or lack of experience to drug formulation and delivery could lead to false negative results in animal studies?
Jens Eckstein: June, that might be true; however, it is dangerous to optimize compounds toward rodent pharmacokinetics.
June Kinoshita: Jens, can you elaborate on your comment?
Jens Eckstein: Rodent pharmacokinetics can be very different from human pharmacokinetics, and you could have spent a lot of time and money to get it right with mice only to find out that the pharmacokinetics profile does not work for humans. If one wants to show the drug works, then go the intracranial route and do not worry too much about the pharmacokinetics in mice.
Gabrielle Strobel: Jens, there are a few vaccine approaches in AD that use the nasal route. Will drugs that come in through the nasal epithelium spread far enough in the brain, though?
Howard Fillit: Gabrielle, there are two wellestablished routes of delivery by intranasal method: through olfactory and trigeminal nerve pathways. Both allow rapid delivery to the entire brain through specific routes. These have been worked out recently. Think about cocaine: It gets almost immediately to the hippocampus.
Gabrielle Strobel: Howard, does this apply equally to small molecules like cocaine and larger molecules like proteins, that is, an immunization antigen?
Howard Fillit: The advantage of intranasal delivery, by the way, is fewer systemic side effects. And yes, peptides are fairly rapidly transported to the brain. Vaccination is a different matter; that actually happens in the intranasal epithelium, not the brain. Frank Longo: Eli, I have the same sense you do. If one argues that synaptic function is one of the first functions to lose, though, perhaps cognitive testing would pick up an effect prior to looking at path changes, etc. I think it depends on which model and the mechanism of the compound being tested.
Eli Michaelis: Frank, I agree. duced to show feasibility that would make the project much more attractive to venture funds.
Eli Michaelis: June, you are right that it is difficult to bring together the expertise of a pharma company in a single center, but it has to be done if it is going to succeed. You need more than good biology and chemistry; you need a good understanding of pharmaceutics and a know-how of what industry faces in drug development.
Jens Eckstein: Outsourcing means good project management; that is, no matter what you do, you want to have people in the effort with expertise in process development/formulation/delivery.
